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Purpose. Development and characterization of an in situYforming, osteoconductive, and growth
factorYreleasing bone implant.
Methods. Injectable in situYforming scaffolds were prepared from a 2% (m/v) alginate solution,
tricalciumphosphate (TCP) granules, and poly(lactide-co-glycolide) microspheres (MS), loaded with the
osteoinductive growth factor insulin-like growth factor I (IGF-I). Scaffolds were prepared by mixing the
components followed by hydrogel formation through calcium carbonateYinduced physical cross-linking
of the alginate at slightly acidic pH. Physical-chemical properties and cell biocompatibility using
osteoblast-like cells (MG-63 and Saos-2) of these scaffolds were investigated.
Results. The addition of TCP to the alginate resulted in reduced swelling and gelation time and an
increase in stiffness. Osteoblast-like cells (MG-63 and Saos-2) did not show toxic reactions and adhered
circumferentially to the TCP granules surface. The addition of the IGF-I MS resulted in an up to seven-
fold increased proliferation rate of MG-63 cells as compared to scaffold preparations without IGF-I MS.
The alkaline phosphate (ALP) activityVa parameter for osteblastic activityVincreased with increasing
amounts of TCP in Saos-2 loaded composite scaffolds.
Conclusions. A prototype in situYhardening composite system for conformal filling of bone defects
supporting osteoblastic activity for further clinical testing in relevant fracture models was developed and
characterized.
KEY WORDS: Drug delivery systems; sustained drug delivery; Insulin-like growth factor I; Bone
healing; osteoinduction.
INTRODUCTION
Injectable, in situ gel-forming matrices as therapeutic
carriers for the treatment of musculoskeletal disorders offer
several advantages over solid implants: flowable material do
establish conformal filling in vivo during tissue (re)-genera-
tion thus avoiding gaps leading to fibrous encapsulation or
scar formation, offer the possibility to co-administer thera-
peutic agents (e.g., growth factors) or cells, and permit min-
imally invasive administration (1). Injectable scaffolds for
bone regeneration have been fabricated using inorganic
materials, e.g., calcium phosphate (2), bioactive glass (3),
synthetic polymers, e.g., poly(ethylene glycol) (4), poly(pro-
pylene fumarate) (5) and natural polymers, e.g., gelatin,
hyaluronic acid, fibrin, collagen, alginate and chitosan (6).
Many of these inorganic fillers and polymeric systems have
been developed in the past, but all of these materials bring
some difficulties that leave room for significant improve-
ment. These difficulties revolve around issues of biocompat-
ibility, biodegradation, toxicity, in situ hardening to obtain
conformal filling, mechanical integrity, or the possibility to
deliver drugs supporting the healing processes. This study
describes the combination of an alginate gel as an in situ
hardening system, tricalciumphosphate (TCP) as an osteo-
conductive filler and a slow release formulation of an os-
teoinductive protein, insulin-like growth factor I (IGF-I), in
an effort to meet the requirements for bone fillers men-
tioned above.
Alginates are seaweed derived, gel-forming polysaccha-
rides composed of 1,4-linked "-D-mannuronic (M) and a-L-
guluronic (G) residues with varying proportions, forming
physical gels in the presence of divalent cations such as
calcium (7). The time for gelation can be controlled using
poorly water-soluble calcium salts such as CaCO3 or CaSO4
(8). Alginates have a long history as injectable cell-delivery
vehicles, cell-immobilization matrices or drug delivery sys-
tems for a variety of biological agents (7). Alginates were
associated with inflammatory reactions (9), which were
reduced by the use of ultrapure alginate with low M and
high G block content. The M and the MG blocks, but not the
G blocks were shown to stimulate cytokine production (10).
The G to M block ratio is also important to control gel
strength, with higher G contents resulting in higher me-
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chanical strength (11). A major drawback in using gelsV
including alginate gelsVto fill bone defects is their insuffi-
cient mechanical support and poor mechanical integrity once
the system is implanted. Therefore, additives are required
to adjust the system to the mechanical needs. Suitable
materials for this purpose are bioceramics such as tricalcium
phosphates (TCP) and hydroxyapatite (HA) creating an os-
teoconductive environment which facilitates cell attachment
(12). The addition of bioceramics as additives to alginate gels
increased the osteoconductive potential and the mechanical
properties of the implant as compared to the gel alone. Fur-
thermore, the composite can be rendered osteoinductive
through the incorporation of drugs, such as growth factors.
Generally, osteoinduction requires prolonged presence of
growth factors at a frequency and modality appropriate to
the disease. Recently, a drug delivery system based on poly
(lactide-co-glycolide) (PLGA) microspheres (MS) has been
developed for IGF-I, and was shown to provide a controlled
and sustained IGF-I release for up to 13 days (13). The IGF-I
MS drug delivery system demonstrated successful osteoin-
duction in two different experimental fracture models per-
formed in large animals (14).
The goal of the present study was to prepare in
situYhardening composites, based on i) an alginate hydrogel
matrix formulated with ii) "-TCP granules and iii) a drug
delivery system with a sustained and controlled release of
IGF-I. The composites were characterized in vitro including
microstructure, degradation, swelling and gelation kinetics,
mechanical properties, and drug release patterns (for study
design see Table I). The proliferative effect of IGF-I released
from the MS and the influence of increasing amounts of
"-TCP granules on alkaline phosphatase (ALP) activity were
analyzed using osteoblast-like cells in combination with this
novel alginate-"-TCP composite.
MATERIALS AND METHODS
Reagents
IGF-I was kindly supplied by Genentech (South San
Francisco, CA, USA). Beta-tricalcium phosphate ("-TCP)
granules (calc-i-oss) with a size of 100 to 300 2m was gifted
from Degradable Solutions AG (Schlieren, Switzerland).
Pharmaceutical grade high-viscosity sodium alginate (Ma-
nugel GMB, ISP Technologies, Girvan, Scotland) was a
gift from Staerkle & Nagler AG (Zurich, Switzerland).
End-group uncapped poly(lactide-co-glycolide) (PLGA)
50:50 (Resomer RG502H) with a molecular weight of 14
kDa was from Boehringer-Ingelheim (Ingelheim, Germany).
Polysorbate 20 (Tween 20) was from Ha¨nseler (Herisau,
Switzerland). Unless specified otherwise, all other sub-
stances used were of pharmaceutical or analytical grade
and purchased from Fluka (Buchs, Switzerland). Cell
culture reagents were from Invitrogen (Basel, Switzerland)
except otherwise specified.
Composite Preparation
For the preparation of in situ gelling alginate-"-TCP
composites, 2.5% alginate solutions in deionized water or in
0.9% NaCl with 10 mM glucose (for cell culture experiments)
were prepared. Typically, 5 mg calcium carbonate (Merck,
Darmstadt, Germany) was suspended per ml 2.5% alginate
solution. 0.25 ml of a fresh 0.2 mM aqueous solution of
D-gluconic acid lactone (GDL) (Sigma, St. Louis, MO, USA)
was stirred into 1 ml of the alginate-CaCO3 suspension to
initiate retarded gelation of the alginate matrix. A molar
ratio of 0.54 of calcium ions to alginate carboxyl groups was
used. Cylindrical composites were prepared by injecting 100
2l of the above alginate-CaCO3-GDL mixture into the wells
of a 96-well plate. Before complete gelation, the alginate gel
was supplemented with either "-TCP granules (10, 25, 50 or
75 mg), IGF-I microspheres (IGF-I MS) as delivery system
for IGF-I, or combinations thereof (Table I). IGF-I MS were
prepared by microencapsulating IGF-I into end-group un-
capped 14 kDa poly(lactide-co-glycolide) 50:50 (PLGA)
(Resomer RG502H, Boehringer-Ingelheim, Ingelheim, Ger-
many) by a double-emulsion solvent evaporation technique
as previously described (13). The IGF-I dose per composite
(83 2g IGF-I/cm3) was chosen in analogy to doses of
microencapsulated IGF-I shown to induce bone healing of
circular (8 mm diameter; total IGF-I dose was 80 2g/cm3) and
Table I. Study Design
Physical-chemical properties Cell assays
Scaffolds ESEM Swelling Gelation Degradation
Mechanical
testing
MG-63
(DNA)
Saos-2
(ALP/DNA) IGF-I release
ALa + + + + + + +
AL/TCP10
b + + + + +
AL/TCP25
b + + + + +
AL/TCP50
b + + + + + + +
AL/TCP75
b + + + + +
AL/MSplac
c + +
AL/TCP50/MSplac
b,c + +
AL/IGF-I MSd + + +
AL/TCP50/IGF-I MS
b,d + + +
a AL: alginate matrix.
b AL/TCPX: alginate matrix + X mg TCP per scaffold.
c AL/MSplac: alginate + placebo (empty) microspheres (MS).
d AL/IGF-I MS: alginate + IGF-I MS.
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segmental (10 mm gap; total IGF-I dose was 100 2g/cm3)
femoral defects in sheep (14).
IGF-I Loading and Release
IGF-I loading was determined as described before (15).
Briefly, 50 mg of microspheres were dissolved in 0.3 ml
DCM. Then, 0.7 ml of acetone were added, and the vial
vortexed and centrifuged at 20,000 rcf for 5 min. The
supernatant was removed, and 0.9 ml of a 3:1 acetone:DCM
mixture was added (n = 3). This washing procedure was
repeated three times. Finally, the residue was dissolved in
0.1 M acetic acid. IGF-I was assayed by HPLC using a Merck
system (Du¨bendorf, Switzerland) consisting of a sample
cooler, an autoinjector (A4000), a computer interface
(A6000), a pump (6200A), and UV (L4250) and fluorimetric
(F 1050) detectors. Separation was performed on a Zorbax
300SB CN column (150  4.6 mm) at 40-C, under gradient
conditions at a flow rate of 0.8 ml/min. Two eluents were
used, (A) consisting of 5% acetonitrile and 0.2% trifluoro-
acetic acid (TFA) in water and (B) 80% acetonitrile and
0.2% TFA in water. The solvent was initially composed of
74% (v/v) eluent A. The solvent was changed over 30 min to
100% eluent B. Then, initial conditions were set to wash the
column. IGF-I was detected at 214 nm and quantified by
measuring the peak area.
In vitro release from IGF-I loaded microspheres as a
function of loading, presence of TCP granules, alginate gel,
or both was determined in 1.5 ml release medium (50 mM
sodiumacetate, 100 mM sodiumchloride, 0.02% Polysorbate
20, 0.02% sodiumazide, pH 5.4; release medium was chosen
to preserve IGF-I structure and activityVno effect of sto-
rage at 37-C on IGF-I stability (HPLC, ELISA) or bio-
activity (MG-63 cell culture) was observed for control IGF-I
solutions diluted in this release medium (measured at day 0
and day 3; data not shown). The following formulations
were evaluated: i) 8.3 2g IGF-I in 11.2 mg MS with 50 mg
TCP granules suspended in 100 2l alginate matrix, ii) 16.6 2g
IGF-I in 22.4 mg MS with 50 mg TCP granules suspended
in 100 2l alginate matrix, iii) 8.3 2g IGF-I in 11.2 mg MS, no
TCP, no alginate iv) 8.3 2g IGF-I in 11.2 mg MS, no TCP
and suspended in 100 2l alginate matrix, and v) 8.3 2g IGF-
I in 11.2 mg MS with 50 mg TCP granules, no alginate. The
release medium was fully exchanged with fresh medium
after 9.5, 32, 53, 72, 97 h, and 7, 10, 14, 21, and 28 days,
respectively. Medium samples were immediately frozen at
j20-C (freezing has no effect on stability (HPLC, ELISA),
or bioactivity (MG-63 cell based proliferation assay; data
not shown), and analyzed using an IGF-I enzyme-linked
immunosorbent assay (ELISA; DuoSet Human) according to
the manufacturer’s protocol (R&D Systems, Minneapolis,
MN; n = 3Y4).
Environmental Scanning Electron Microscopy (ESEM)
The microstructures of the composites were character-
ized using an ESEM (FEI/Philips XL 40, FEI Company,
Hillsboro, OR) at 10 kV. Composites were washed with
deionized water to remove salt before measuring and cut
longitudinally in half. Composites were analyzed without any
further pretreatment by ESEM.
Swelling Kinetics
Composites were incubated in 2 ml 0.1 M Tris buffer
(pH = 7.4) in 12-well plates at 37-C, and wet weights were
determined at different time points. The degree of swelling
(Q), was calculated according to the following formula: as
elsewhere described (16):
Q ¼ 1=p
 
Qm

s þ 1

p
 1h i1
where p is the polymer density (calculated for each com-
posite, mg/mm3), s is the density of water, and Qm is the
swelling ratio, defined as the mass ratio of absorbed water to
the dried gel. To obtain Qm, the weight of swollen composites
and the weight of dried composites following drying over
night at 50-C were measured.
Rheological Measurements
The rheological properties were examined using a
HAAKE RheoStress 600 rheometer (Thermo Electron
GmbH, Karlsruhe, Germany) with a plateYplate measuring
geometry with a diameter of 35 mm and a plate to plate
distance of 1 mm. To avoid water evaporation during mea-
surements a solvent trap system served to create a humified
atmosphere around the probe.
Gelling kinetics as a function of the amount of supple-
mented "-TCP granules (0, 10, 25, 50 and 75 mg/composite)
added to the alginate gel were characterized by determination
of storage (G0) and loss (G00) moduli from the oscillating mea-
surements with a controlled deformation of 0.05% at a fre-
quency of 1 Hz. Gelation was initiated by adding GDL, then
1 ml probe was placed on the rheometer plate preheated
to 37-C. Gelation time was estimated at the intersection of
G0 and G00 (17).
Composite Degradation
Degradation of different composite preparations was
evaluated by monitoring the changes in weight loss over time.
Composites (n = 6) were incubated in minimum essential
medium (MEM) containing 10% FBS, supplemented with
penicillin (100 units/mL)/streptomycin (100 2g/mL) and
0.01% sodium azide at 37-C.
Mechanical Testing
To evaluate the influence of different amounts of "-TCP
granules on the mechanical properties of the gels, formula-
tions with 0, 10, 25, 50, or 75 mg of "-TCP granules per 100
2l alginate were molded into the wells of a 96-well plate and
allowed to cure over night before testing. Three sample
composites of each formulation were tested. Uniaxial com-
pression was performed on a mechanical tester (Instron 1122;
Instron Corp., Canton, MA, USA), equipped with a 50 N
loading cell at a deformation rate of 1 mm/min. An initial
load of 0.01 N was applied. Young’s Modulus was calculated
from the slope of the strain-stress curve within the linear
region up to 10% strain.
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Cells, Cell-Seeding, and Culture of Three-Dimensional
Composites
Two human osteoblast-like cell lines MG-63 and Saos-2
(ATCC, Manassas, VA, USA) were used in these experi-
ments. MG-63 cells were cultured in minimum essential
medium (MEM) containing 10% heat inactivated FBS,
supplemented with a mix of penicillin (100 units/ml), strep-
tomycin (100 2g/ml), amphotericin B (5 2g/ml), L-glutamine
(2 mM), sodium pyruvate (1 mM), and nonessential amino
acids (0.1 mM) at 37-C in a humidified atmosphere containing
5% CO2. Saos-2 cells were cultured in DMEM (Dulbecco’s
modified Eagle medium) with L-glutamine (2 mM), D-glucose
(4500 mg/ml), and sodium pyruvate (1 mM) containing 10%
heat inactivated FBS, supplemented with a mix of penicillin
(100 units/ml), streptomycin (100 2g/ml), amphotericin B
(5 2g/ml) and nonessential amino acids (0.1 mM). Cells were
harvested at 90% confluence, counted, and immediately used
to seed the composites.
Before complete gelation of the composites, 2  104
MG-63 or Saos-2 cells were injected into the cylinders (n = 6)
and thoroughly mixed into the scaffold matrix. Composites
were allowed to harden at 37-C in a humidified atmosphere
containing 5% CO2 for 2 h. After removal from the 96-well
plate, they were transferred to 24-well plates and cultured in
1 ml cell culture medium for 2 and 7 days under mild
agitation (160 minj1) on a horizontal shaker. Medium was
exchanged after 2 h to avoid calcium deprivation of the
culture medium and, thereby, impact the cells’s performance.
Medium was thereafter exchanged every other day. Alginate
gels without cells were cultured in the same way and used as
controls.
DNA Quantification
DNA quantification was performed to assess cell prolifer-
ation in the different composite formulations. After incuba-
tion of cell-seeded and unseeded (control) composites for 2 to
7 days, composites were rinsed three times with PBS and lysed
in 0.2% Triton X-100, 10 mM Tris (pH = 7.4) containing
54 mM EDTA for 2 days. Supernatants were used to quantify
total DNA content in the composites using a fluorescence
assay (PicoGreen dsDNA Quantitation Kit, Molecular
Probes, Leiden, Netherlands) according to the instruction of
the manufacturer.
Alkaline Phosphatase Activity
Saos-2-cell seeded and composites without cells were
cultured for 2 and 7 days, rinsed three times with PBS and
lysed in 0.2% Triton X-100 (Fluka, Buchs, Switzerland),
10 mM Tris (pH = 7.4) containing 54 mM EDTA at 4-C.
Supernatants of lysed composites were used to measure ALP
activity as described before (18). For this, 100 2l aliquots of
the lysates were added to 100 2l working reagent in a 96 well
culture plate for 30 min at 37-C. The working reagent
consisted of a 1:1:1 (v/v/v) mixture of 0.5 M 2-amino-2-
methylpropanol (pH = 10.5) (Sigma, Steinheim, Germany),
5 mM p-nitrophenolphosphate, and 5 mM magnesium chlo-
ride. After development of colour, the time was recorded and
the reaction stopped by adding 100 2l of 0.3 M sodium
hydroxide, and the final absorbance was read at 405 nm using
a microplate reader (ThermoMax, Molecular Devices, Sunny-
vale, CA). ALP activity was expressed as nanomoles p-
nitrophenol per ng DNA and normalized to the time needed
for the reaction in minutes.
Confocal Fluorescence Microscopy (CLSM)
To assess MG-63 cell viability and morphology in the
composites, an in situ fluorescence viability study was
performed with a LiveYDead viability/cytotoxicity kit (Mo-
lecular Probes). Cell seeded composites (MG-63 cells)
cultured for 2 and 7 days were washed three times with
PBS, and then incubated in 5 2M Calcein AM, 5 2M
ethidium homodimer-1 and 10 2M Hoechst 33342 (Molecular
Probes) for 30 min in PBS. Composites were cut longitudi-
nally in half and incorporated cells were observed immedi-
ately. Brightfield and fluorescence images were obtained
with a Zeiss 410 inverted microscope with Plan-Neofluar
10, 20, and 40 objectives (Zeiss, Jena, Germany),
equipped with Argon (488 nm) and HeNe (543 nm) lasers
for fluorescence. Background fluorescence was determined
by analyzing composites without cell seeding. Two-dimen-
sional multi-channel image processing was performed using
IMARIS (Bitplane AG, Switzerland).
Statistics
Statistical analysis of data was performed by one-way
analysis of variance (ANOVA) and TukeyYKramer proce-
dure for post hoc comparison using Minitab (Minitab Inc.,
State College, PA, USA). p values less than 0.05 were
considered statistically significant. Areas under the Curve
(AUC) were determined using Sigma Plot (Systat, Point
Richmond, CA).
RESULTS
Composite Characteristics
The alginate gel surface was generally flat, nonporous
and covered with protuberances as determined by ESEM
(Fig. 1A). The addition of "-TCP granules into the alginate
matrix resulted in a porous microstructure with granule sizes
ranging from 100 to 300 2m (Fig. 1B). IGF-I loaded MS with a
mean diameter of about 50 2m mixed to the alginate gel (Fig.
1C) also increased the gel porosity. Addition of IGF-I MS
together with "-TCP granules resulted in a homogenous
distribution of both particle types and the gel matrix was more
porous than that of the pure alginate gel (Fig. 1D). The
swelling curves of all formulations were characterized by a
rapid increase of the swelling ratio Q within the first hour of
incubation, followed by a slight shrinkage of the gel matrix
resulting in a plateau after about 4 h (Fig. 2). The total
amount of composite swelling was inversely dependent on
the amount of "-TCP granules added. The alginate matrix
without "-granules had a swelling ratio of 31.0 T 1.8, whereas
the addition of "-TCP granules resulted in a decrease of
the swelling ratio from 11.6 T 0.9 to 4.1 T 0.7 of 10% and 75%
(all w/w) addition of TCP granules to the gel, respectively.
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For the preparation of the composites, GDL was used to
initiate retarded gelation. The lactone hydrolyses slowly and,
thereby, gradually lowers the pH resulting in a slow release
of calcium ions from CaCO3, which becomes soluble at lower
pH (19). Gelation time was found to depend on the amounts
of "-TCP granules added to the gel matrix (Fig. 3). An
inverse relation between gelation time and "-TCP granule
amount was found. The alginate gel without "-TCP granules
gelated within 35 minutes as compared to 15 minutes for the
composites with 75% "-TCP granules.
Simulated body fluid was used to study degradation
kinetics of alginate and alginate composites (Table II). After
27 days of incubation, alginate gels had a weight loss of 55%
and composites a weight loss between 33 and 39%. The
presence of placebo microspheres did not effect the degra-
dation (Table II).
The mechanical properties of the composites were
measured in compression tests and with increasing amounts
Fig. 2. Swelling behavior over 24 h of alginate gel matrix (AL) and
composite scaffolds (AL/TCPX) with different amounts (X) of TCP
granules embedded in the gel matrix as indicated by the numbers.
Fig. 1. Environmental scanning electron microscopy (ESEM) of surface morphology. (A) alginate matrix, (B)
alginate with "-TCP granules (AL/TCP50), (C) alginate with IGF-I microspheres (AL/IGF-MS), (D) alginate
matrix with "-TCP granules and IGF-I MS (AL/TCP50/IGF-MS). IGF-I MS are highlighted by arrows.
Fig. 3. Oscillatory rheological measurements were used to analyze
the gelling kinetics of the matrices depending on the amounts of "-
TCP granules (0, 10, 25, 50 and 75 mg/scaffold) added to the alginate
gel. The gel point was estimated by the crossover of storage (G0) and
loss (G0 0) modulus highlighted at the curve of the alginate gel by an
arrow.
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of "-TCP granules in the alginate matrix, Young’s modulus
(YM) increased in a non linear way (Fig. 4). A 15-fold in-
crease in this modulus was observed for the composite with
75% "-TCP granules (176.8 T 35.6 kPa) as compared to the
alginate gel without "-TCP granules (11.8 T 0.6 kPa).
IGF-I Loading and Release
The total loading was 0.738 T 0.139 2g IGF-I per mg
PLGA MS as determined by HPLC. For evaluation of in
vitro IGF-I release, 11.2 mg of IGF-I loaded PLGA MS,
corresponding to a total dose of 8.3 2g IGF-I, was incorpo-
rated into 100 2l of alginate matrix, with or without addition
of 50 mg "-TCP granules. Additionally, similar composites
were prepared with 22.4 mg microspheres, corresponding to
16.6 2g IGF-I, to evaluate the effect of total IGF-I dose on
release patterns (Fig. 5A and B). Generally, the release
curves were similar for the high loading (total IGF-I dose
16.6 2g) and the lower loading (total IGF-I dose 8.3 2g).
However, the initial burst was significantly higher for the
higher IGF-I loading after 9.5 h (p < 0.05) and significantly
higher for the lower loading after 32 h (p < 0.05). This initial
release was followed by a lag phase lasting up to 7 days and
characterized by a minimal release of IGF-I. From day 7 on,
a steep increase in IGF-I release was simultaneously ob-
served for both formulations, with the higher loaded formu-
lation releasing significantly more IGF-I than the lower loaded
formulations at all time-points (p < 0.01 or p < 0.05). A
difference between the groups after 28 days when compared
to the 21 days time-point was observed, with a declining
release rate for the formulation with the higher loading (p <
0.05), while the release from the formulation with the lower
loading, although not statistically significant, continued to
rise (Fig. 5A). This finding, along with an apparent increase
in standard deviations observed for all formulations after
28 days as compared to previous time-points, suggest the
beginning decline of IGF-I release from the formulations
(Fig. 5AYC). The total amount of released IGF-I (AUC) was
more than two times higher for the higher loaded formula-
tion (total IGF-I dose 16.6 2g) as compared to the
formulation with the lower loading (total IGF-I dose 8.3 2g;
p < 0.01; Fig. 5B).
Furthermore, the impact of the alginate matrix, or the
TCP granules, or both on release kinetics and the resulting
areas under the curve were assessed (Fig. 5C and D).
Generally, the release curves were similar for all groups,
characterized by an initial burst (days 1 and 2), a lag phase
with minimum release (days 2 to 7) and a steep increase in
IGF-I release form day 7 on. The curve progression was
reproducible, besides from the initial burst and after 28 days,
when the standard deviations were larger as compared to the
other time-points. The presence of TCP minimally influenced
the release as compared to the IGF-MS alone (p < 0.05).
However, the presence of the alginate matrix, with or without
addition of TCP granules, resulted in a decrease of the AUC
as compared to the IGF-MS alone or the mixture of IGF-I
with TCP granules (p < 0.01; Fig. 5C and D).
Cell Viability, Proliferation and ALP Activity
Cellular viability, proliferation, IGF-release kinetics and
activity within the composites were tested with two different
osteoblast-like cell lines (MG-63 and Saos-2; for study design
Fig. 4. Young’s Modulus (YM) of composite scaffolds with different
amounts of "-TCP granules (0, 10, 25, 50, 75 mg/scaffold).
Table II. In Vitro Degradation Kinetics of Alginate Scaffolds with Different Amounts of TCP (10, 25, 50, 75 mg) with or without Placebo
Microspheres (MSplac)
Weight (%)
Scaffolds 1 day 2 days 7 days 14 days 21 days 27 days
AL/TCP10
b 93.8 T 2.7 84.1 T 2.6 77.6 T 2.2 68.6 T 2.0 62.7 T 4.5 61.0 T 3.1
AL/TCP25
b 96.0 T 5.6 88.1 T 6.2 79.9 T 6.1 73.6 T 6.2 68.9 T 8.6 67.0 T 8.1
AL/TCP50
b 65.1 T 9.4 69.7 T 9.1 65.2 T 9.5 67.0 T 10.2 65.2 T 9.4 61.7 T 4.5
AL/TCP75
b 87.3 T 3.5 89.9 T 8.3 84.7 T 10.6 82.6 T 13.2 79.5d e
ALa 89.6 T 7.1 83.6 T 7.6 73.8 T 6.6 66.3 T 7.2 60.9 T 6.9 45.4 T 12.8
AL/MSplac
c 68.9 T 17.0 62.0 T 11.5 61.7 T 6.8 73.3 T 8.2 75.5 T 8.2 60.0 T 8.7
AL/TCP50/MSplac
b,c 69.1 T 18.8 73.1 T 19.1 71.1 T 19.2 77.3 T 21.4 73.4 T 19.4 67.3 T 17.7
a AL: alginate matrix.
b AL/TCPX: alginate matrix + X mg TCP per scaffold.
c AL/MSplac: alginate + placebo (empty) microspheres (MS).
d No standard deviation due to scaffold degradation.
e Degraded.
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see Table I) (20,21). The cells were carefully mixed with the
alginate formulation during gel formation avoiding high
shear forces. Cylindrical alginate gels (dimensions of 5  4
mm), loaded with IGF-I PLGA MS and MG-63 cells, were
prepared with or without TCP granules. These constructs
were incubated in cell culture medium for 7 days at 37-C
(Fig. 6). The IGF-I concentrations in the supernatant of MG-
63 cell seeded gels was characterized by an initial burst of
about 12% of the total loading. This phase was followed by a
phase of minimal IGF-I release as measured by ELISA.
After 7 days about 18% of the total encapsulated IGF-I was
released and no differences between the groupsVTCP
loaded or unloadedVwere observed (Fig. 6).
The MG-63 cells, a cell line frequently used to assess
IGF-I bioactivity (22,23), were selected to examine cellular
proliferation based on total DNA quantification (24). No
significant differences in proliferation rates were observed
after 2 days, except for the formulation with "-TCP granules/
placebo MS, where DNA concentration was reduced to 50%
of the DNA initially present in the cell seeded composite
( p < 0.05) (Fig. 7A). After 7 days, all formulations without
IGF-I MS dropped to significantly lower DNA contents as
compared to the alginate gel matrix (p < 0.01). CLSM images
showed that MG-63 cells were localized in cell clusters within
the alginate gel with no apparent adherence to the gel matrix
(Fig. 7B, panel a). In contrast, the presence of "-TCP gran-
ules resulted in circumferential adherence of the cells to the
rough and porous "-TCP granule surface (Fig. 7B, panel b).
Very few dead cells were observed, except for placebo MS
Fig. 5. IGF-I release over 28 days as determined by ELISA. (A) IGF-I release and (B) IGF-I area under the curve
(AUC) from alginate matrix formulations loaded with TCP granules and a total IGF-I dose, encapsulated in
PLGA MS, of 8.3 2g or 16.6 2g, respectively. (C) IGF-I release kinetics and (D) IGF-I area under the curve from
formulations containing 8.3 2g IGF-I, encapsulated in PLGA-MS. The formulations were composed of IGF-I
PLGA MS with TCP granules in alginate matrix (IGF-MS/TCP/alginate), IGF-I MS only (IGF-MS), IGF-I MS in
alginate matrix (IGF-MS/alginate), and IGF-I MS with TCP granules (IGF-MS/TCP). (**p < 0.01, *p < 0.05).
Fig. 6. Cumulative IGF-I release from PLGA MS embedded in
alginate gel matrix with or without "-TCP granules as measured in
the supernatant of the cell culture studies (MG-63 cells).
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formulation, where a few dead cells were observed particu-
larly close to placebo MS (Fig. 7B, panel c). The total cell
number appeared to drop in regions more than 500 2m below
the surface, as assessed qualitatively by CLSM.
A marker of osteogenic activity, alkaline phosphatase
(ALP) activity, was analyzed as a function of composite
formulations using the osteoblastic Saos-2 cell line (for study
design see Table I). An increase in ALP activity is char-
acteristic for the mineralizing osteoblast (25). Because the
MG-63 cells express very little ALP (26), Saos-2 cells were
used to examine ALP activity as a function of the different
formulations (27). The influence of increasing amounts of
"-TCP granules (0, 10, 25, 50, 75 mg/composite) on ALP
activity was also determined (Fig. 8). In all formulations ALP
activity normalized to DNA content was significantly higher
at day 7 as compared to day 2 (p < 0.05) (Fig. 8A). ALP
activity was more than 3 times higher in composites contain-
ing "-TCP granules (Fig. 8A) as compared to the alginate
matrix prepared without "-TCP granules at days 2 and 7,
respectively ( p < 0.01). ALP activity increased from 29.6 T
9.5 to 108.3 T 77.8 (nM pNP minj1 ngj1 DNA) after 2 days,
and from 47.2 T 15.7 to 435.3 T 137.4 (nM pNP minj1 ngj1
DNA) after 7 days with increasing amounts of "-TCP
granules (10, 25, 50, 75 mg per composite), respectively.
The amount of DNA, unlike in MG-63 cells (Fig. 5A),
decreased from day 2 to 7, with significantly lower DNA
contents for preparations with increasing proportions of "-
TCP granules ( p < 0.05 or 0.01) (Fig. 8B).
DISCUSSION
Injectable in situYhardening composites were developed
consisting of an alginate hydrogel matrix with incorporated
"-TCP granules and PLGA-MS for sustained IGF-I release
as an option for minimally invasive osteoconductive and
osteoinductive treatments of bone defects. Physicochemical
properties and cellular biocompatibility of these composite
scaffolds were tested (for study design see Table I). The
composite formulations showed reduced swelling, faster
gelation and improved compressive stiffness with increasing
amounts of incorporated "-TCP granules as compared to
alginate gel alone. All scaffolds were stable in a simulated
body fluid for up to 4 weeks. The IGF-I release and the total
amount of released IGF-I were determined with and without
TCP granules or alginate matrix over 28 days. Osteoblast-like
cells (MG-63 and Saos-2) seeded on the scaffolds showed
good cell viability after 2 and 7 days in particular in the outer
scaffold regions with cells predominantly adhering to the
surface of TCP granules. The release of bioactive IGF-I from
MS incorporated in the scaffolds significantly enhanced the
proliferation rates of MG-63 cells.
The successful use of bone defect fillers requires detailed
knowledge and control of swelling, gelation time, degrada-
tion and mechanical properties of the implant. The addition
of "-TCP granules to the alginate hydrogel resulted in more
rigid material characteristics (Fig. 1B) as compared to the
alginate gel alone (Fig. 1A) and, therefore, in decreased
Fig. 7. (A) DNA content analyzed from different scaffold formulations (AL: alginate, TCP: "-TCP granules, MS:
microspheres) seeded with osteoblast-like cells (MG-63) cultured for 2 (light gray bars) and 7 (dark gray bars)
days. (**p < 0.01, *p < 0.05). (B) CLSM images after 7 days of culture of MG-63 cells seeded on (a) alginate, (b)
composites with 50 mg TCP granules, or with (c) placebo microspheres (MS). Cells were stained with calcein and
ethidium homodimer to distinguish living (green fluorescent) and dead cells (red fluorescent); see arrow in (c).
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swelling ratios (Fig. 2) and increased mechanical stability
(Fig. 4). However, in comparison to the compressive modu-
lus of human trabecular bone (50 MPa) (28), the compres-
sive modulus of the developed composites (up to 200 kPa)
clearly demonstrated that the alginate "-TCP composites
should find application in load-bearing bones together with
external stabilization, e.g., by the use of a fixateur externe or
plates.
The gelation time of the scaffolds shortened with
increasing amounts of "-TCP granules (Fig. 3). Faster
gelation could be a result of the higher initial viscosity due
to incorporated "-TCP granules as seen in the higher initial
values of the storage modulus G0 (Fig. 3). Furthermore,
calcium release from the surface of TCP granules may lead to
increased gelation times, especially at low pH as a result of
the addition of the GDL. However, generally only minimal
amounts of extra calcium are released from "-TCP, even at
slightly acidic pH and, therefore, most likely this effect had
an insignificant impact on the formation of the composites.
For example, calcium release from "-TCP during in vitro
degradation at pH 5.6 was described to be in the range of 54
ppm after 1 h (29).
The in vitro degradation of our formulations (mass loss
of 33 to 55% after 4 weeks; Table II) was in the range of in
vivo degradation rates reported for alginate formulations,
which were implanted subcutaneously into the back of mice
and had a mass loss of almost 55% after 6 weeks (30).
The in vitro release pattern was evaluated at pH 5.4 over
28 days. This non-physiological release medium was chosen
to preserve IGF-I structure and activity overtime, as we have
shown before (VL unpublished data). The presence of
alginate significantly reduced the total amount of released
IGF-I (Fig. 5D), a finding which has been previously
reported for other proteins including bovine serum albumin
(BSA) (31), basic fibroblast growth factor (bFGF) (32), and
vascular endothelial growth factor (VEGF) (31,33Y36). IGF-I
has a pI of 8.4 (37,38), whereas the pKa value for alginate is
about 3.5 (39). At pH 5.4 (Fig. 5) or 7.4 (Fig. 7) IGF-I carries
a positive net charge and, therefore, can interact electrostat-
ically with alginate, which is negatively charged. Similar find-
ings were reported for VEGF (pI 8.5) (31), whereas BSA
(pI 4.7), has much lower electrostatic interactions (31,40).
For further development of the IGF-I formulations BSA
might, therefore, be added as an excipient to mask the elec-
trostatic IGF-alginate matrix interaction, in an effort to
strictly confine the control of drug delivery to the degrading
PLGA-MS while minimizing the impact of the alginate
matrix.
The development of this formulation towards clinical use
needs further studies detailing the osteoinductive responses
kick-started upon implantation into defect sites. Besides from
the important information revolving around in vivo perfor-
mance, further questions can be addressed, revolving around
optimized kinetics. More specifically, the release kinetics
presented here, as determined at pH 5.4 (Fig. 5) and corrobo-
rated for time points earlier than 7 days at pH 7.4 (Fig. 6),
coincide with the chondrogenic (days approx. 7Y25 post-
trauma) and osteogenic (days approx. 12Y30 post-trauma)
phases in physiological, endochondral bone healing, as detailed
for segmental and circular defects in mice, rats (41Y43), and
sheep (L.M., unpublished results). During these physiologic
healing events, both the chondrogenic and osteogenic phases
are characterized by high expression levels of IGF-I (LM,
unpublished results) (42). Based on the hypothesis that the
defect zone is most susceptible to an IGF-I triggered osteoin-
ductive stimulus when release kinetics match the endogenous
production of IGF-I, the biomimetic release profiles as pre-
sented here might induce more potent osteoinductive stimuli
than other release profiles. Apparently, further studies are
needed to detail the hypothesized advantage of biomimetic
over other release profiles and the presented systems offers
a good platform to start-off working in that direction.
ALP activity of Saos-2 cells seeded into alginate gels
alone was low (Fig. 8A), and significantly increased with
increasing amounts of "-TCP granules added to the gel
matrix. These findings demonstrate that "-TCP granules
supported the osteoblastic activity of Saos-2 cells. The two
cell lines selected in this study (Saos-2 cells and MG-63 cells)
are often commonly referred to as (pre)osteblastic cell lines.
Although a common expression is used for both cell lines, it
should not belie the fact that striking differences do exist
Fig. 8. (A) Alkaline phosphatase (ALP) activity and (B) DNA
content of Saos-2 cells seeded in matrices containing different
amounts of "-TCP granules (0, 10, 25, 50, 75 mg/scaffold). (**p <
0.01, *p < 0.05).
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between them, also reflected by the results reported here,
e.g., by the markedly different proliferation of MG-63 cells
vs. Saos-2 cells, although cultured at identical conditions
(Figs. 7A and 8B). Saos-2 cells, unlike MG-63 cells, exhibit
many features of a well-differentiated osteoblast including
the ability to induce mineralization of their matrix (20,21,44).
It has been described for several progenitor cells that a
progression towards the ultimate phenotype can be correlat-
ed with a decrease in proliferation rates, including osteoblast
progenitors (45). The MG-63 cell line more closely resembles
osteoblastic progenitors in less differentiated stages, whereas
the Saos-2 cell line exhibits more advanced differentiation.
The more advanced stage of Saos-2 cells is also reflected by
the reported results, as these cells showed reduced prolifer-
ation with increasing amounts of "-TCP granules (Fig. 8B), a
result similarly reported for primary osteoblasts derived from
rat calvarial cells (46).
The presented injectable composite system consisting of
an alginate gel, TCP granules, and PLGA-MS for the sus-
tained release of the osteoinductive growth factor IGF-I has
interesting features for orthopaedic applications, combining
the option for conformal filling of the defect, increased
mechanical stability, an osteoconductive environment (TCP
granules and microspheres) with an osteoinductive stimulus
(controlled release of growth factors). This renders this
pharmaceutical system an interesting tool for the treatment
of bone defects and for future animal studies using fracture
models.
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